This systematic review and meta-analysis aimed to summarize the effectiveness and safety of low-dose (<4 mg/kg) versus high-dose (≥4 mg/kg) CsA and other systemic immunomodulatory agents in patients with AD
Cyclosporine (modified) is also used to treat psoriasis (a skin disease in which red, scaly Cyclosporine has an average rating of 9
6 out of 10 from a total of 332 ratings on
1056/NEJMoa021359 Methotrexate and cyclosporine are well-known
The purpose of this study was to compare the efficacy and safety of daily cyclosporine
This noninferiority study, comparing methotrexate versus cyclosporine in patients with
Abstract Cyclosporine A (CsA) is effective in treating moderate-to-severe
Conclusions and relevance: Dupilumab and cyclosporine may be more
Question: In patients with chronic plaque psoriasis, does treatment with cyclosporine or methotrexate lead to higher rates of clearance,and what toxic effects are associated with each treatment? Design: Heydendael and colleagues conducted a randomized controlledtrial comparing the effectiveness and side effects of methotrexate and Ciclosporin, an oral immunosuppressant drug, is a treatment for severe eczema that requires supervision by a dermatologist
5 mg/week) while group B was treated with cyclosporine (2
This study is the first head-to-head comparison of methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis
We evaluated the efficacy and safety of methotrexate and cyclosporine in the treatment of 40 children with severe AD
A set of systemic immunomodulatory drugs including corticosteroids (CS), cyclosporine A (CsA), methotrexate (MTX), azathioprine, mycophenolate mofetil (MMF), and others have been used to control moderate-to-severe AD
Cyclosporine A and short-term methotrexate versus cyclosporine A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from HLA identical sibling: results of a GITMO/EBMT randomized trial
Regarding the primary end point at week 8, methotrexate was inferior to cyclosporine because the proportion of patients with SCORAD 50 was 8% (4 of 50) in the methotrexate arm versus 42% (18 of 43) in the cyclosporine arm
A significant reduction in the cumulative incidence of grades II to IV acute graft versus host disease was observed in the patients who received both methotrexate and cyclosporine (33 percent), as compared with those who were given cyclosporine alone (54 percent) (P = 0
was no significant difference in short-term risk of colectomy between standard-dose induction therapy with infliximab vs cyclosporine in hospitalized patients with corticosteroid-refractory ASUC
Epub 2015 Nov 30
primary end point at week 8, methotrexate was inferior to cyclosporine because the proportion of patients with SCORAD 50 was 8% (4 of 50) in the methotrexate arm versus 42% (18 of 43) in the cyclosporine arm
Methotrexate versus cyclosporine in adults with moderate-to The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings
Setting and design: This multicentre, parallel group (ratio 1 : 1), randomized controlled trial was conducted in a secondary care setting in Egypt
The median duration of cyclosporine treatment was 356 days
The overall drug survival rates were 34, 18, 12 and 4% after 1, 2, 3 and 6 years, respectively
Objectives To compare the effectiveness, quality of life and side‐effects of methotrexate and ciclosporin treatments in a context reflecting normal clinical practice